{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:24:53Z","timestamp":1790767493718,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 EY014801"],"award-info":[{"award-number":["P30 EY014801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["Unrestricted"],"award-info":[{"award-number":["Unrestricted"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12035-019-01857-6","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T15:02:36Z","timestamp":1578063756000},"page":"1952-1965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Gene Therapy with Single-Subunit Yeast NADH-Ubiquinone Oxidoreductase (NDI1) Improves the Visual Function in Experimental Autoimmune Encephalomyelitis (EAE) Mice Model of Multiple Sclerosis (MS)"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-7536","authenticated-orcid":false,"given":"Venu","family":"Talla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwari","family":"Koilkonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"1857_CR1","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/mt.2010.172","volume":"18","author":"DM Markusic","year":"2010","unstructured":"Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, Jayandharan GR, Ling C et al (2010) High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol.Ther. 18:2048","journal-title":"Mol.Ther."},{"key":"1857_CR2","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0166-2236(02)02255-5","volume":"25","author":"MP Coleman","year":"2002","unstructured":"Coleman MP, Perry VH (2002) Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25:532","journal-title":"Trends Neurosci"},{"key":"1857_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","volume":"13","author":"AT Toosy","year":"2014","unstructured":"Toosy AT, Mason DF, Miller DH (2014) Optic neuritis. Lancet Neurol 13:83","journal-title":"Lancet Neurol"},{"key":"1857_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/WCO.0000000000000327","volume":"29","author":"O Aktas","year":"2016","unstructured":"Aktas O, Albrecht P, Hartung HP (2016) Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Curr.Opin.Neurol. 29:199","journal-title":"Curr.Opin.Neurol."},{"key":"1857_CR5","first-page":"247","volume":"308","author":"A Shirani","year":"2012","unstructured":"Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P et al (2012) Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308:247","journal-title":"JAMA"},{"key":"1857_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N.Engl.J.Med 354:899","journal-title":"N.Engl.J.Med"},{"key":"1857_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/01.wco.0000073929.19076.cd","volume":"16","author":"JH Noseworthy","year":"2003","unstructured":"Noseworthy JH (2003) Management of multiple sclerosis: current trials and future options. Curr.Opin.Neurol. 16:289","journal-title":"Curr.Opin.Neurol."},{"key":"1857_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1212\/01.wnl.0000311267.63292.6c","volume":"70","author":"EE Benarroch","year":"2008","unstructured":"Benarroch EE (2008) N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology 70:1353","journal-title":"Neurology"},{"key":"1857_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nm.2324","volume":"17","author":"I Nikic","year":"2011","unstructured":"Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, Bruck W, Bishop D et al (2011) A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat.Med. 17:495","journal-title":"Nat.Med."},{"key":"1857_CR10","doi-asserted-by":"crossref","unstructured":"Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, Flockerzi V, Bruck W et al (2012) TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat.Med","DOI":"10.1038\/nm.3015"},{"key":"1857_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11910-006-0012-0","volume":"6","author":"B Kalman","year":"2006","unstructured":"Kalman B (2006) Role of mitochondria in multiple sclerosis. Curr.Neurol.Neurosci.Rep. 6:244","journal-title":"Curr.Neurol.Neurosci.Rep."},{"key":"1857_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1385\/NMM:3:3:147","volume":"3","author":"B Kalman","year":"2003","unstructured":"Kalman B, Leist TP (2003) A mitochondrial component of neurodegeneration in multiple sclerosis. Neuromolecular.Med. 3:147","journal-title":"Neuromolecular.Med."},{"key":"1857_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1600-0404.1998.tb07301.x","volume":"98","author":"B Kalman","year":"1998","unstructured":"Kalman B, Alder H (1998) Is the mitochondrial DNA involved in determining susceptibility to multiple sclerosis? Acta NeurolScand 98:232","journal-title":"Acta NeurolScand"},{"key":"1857_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/ana.20736","volume":"59","author":"R Dutta","year":"2006","unstructured":"Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB et al (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann.Neurol. 59:478","journal-title":"Ann.Neurol."},{"key":"1857_CR15","doi-asserted-by":"publisher","first-page":"31950","DOI":"10.1074\/jbc.M603717200","volume":"281","author":"X Qi","year":"2006","unstructured":"Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J (2006) Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J.Biol.Chem. 281:31950","journal-title":"J.Biol.Chem."},{"key":"1857_CR16","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1167\/iovs.14-15950","volume":"56","author":"V Talla","year":"2015","unstructured":"Talla V, Koilkonda R, Porciatti V, Chiodo V, Boye SL, Hauswirth WW, Guy J (2015) Complex I subunit gene therapy with NDUFA6 ameliorates neurodegeneration in EAE. Invest Ophthalmol.Vis.Sci. 56:1129","journal-title":"Invest Ophthalmol.Vis.Sci."},{"key":"1857_CR17","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1167\/iovs.14-14688","volume":"55","author":"V Talla","year":"2014","unstructured":"Talla V, Porciatti V, Chiodo V, Boye SL, Hauswirth WW, Guy J (2014) Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis. Invest OphthalmolVisSci 55:5214","journal-title":"Invest OphthalmolVisSci"},{"key":"1857_CR18","doi-asserted-by":"crossref","unstructured":"Talla V, Yu H, Chou TH, Porciatti V, Chiodo V, Boye SL, Hauswirth WW, Lewin AS et al (2013) NADH-dehydrogenase type-2 suppresses irreversible visual loss and Neurodegeneration in the EAE animal model of MS. Mol.Ther","DOI":"10.1038\/mt.2013.104"},{"key":"1857_CR19","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.3201231","volume":"242","author":"DC Wallace","year":"1988","unstructured":"Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ, Nikoskelainen EK (1988) Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242:1427","journal-title":"Science"},{"key":"1857_CR20","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/j.1471-4159.1990.tb05809.x","volume":"55","author":"AH Schapira","year":"1990","unstructured":"Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J.Neurochem. 55:2142","journal-title":"J.Neurochem."},{"key":"1857_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","volume":"54","author":"AH Schapira","year":"1990","unstructured":"Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J.Neurochem. 54:823","journal-title":"J.Neurochem."},{"key":"1857_CR22","doi-asserted-by":"publisher","first-page":"15247","DOI":"10.1073\/pnas.1210059109","volume":"109","author":"M Iwata","year":"2012","unstructured":"Iwata M, Lee Y, Yamashita T, Yagi T, Iwata S, Cameron AD, Maher MJ (2012) The structure of the yeast NADH dehydrogenase (Ndi1) reveals overlapping binding sites for water- and lipid-soluble substrates. Proc.Natl.Acad.Sci.U.S.A 109:15247","journal-title":"Proc.Natl.Acad.Sci.U.S.A"},{"key":"1857_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0076-6879(00)16760-6","volume":"316","author":"WW Hauswirth","year":"2000","unstructured":"Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N (2000) Production and purification of recombinant adeno-associated virus. Methods Enzymol 316:743","journal-title":"Methods Enzymol"},{"key":"1857_CR24","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/bioinformatics\/btw413","volume":"32","author":"D Legland","year":"2016","unstructured":"Legland D, Arganda-Carreras I, Andrey P (2016) MorphoLibJ: integrated library and plugins for mathematical morphology with ImageJ. Bioinformatics. 32:3532","journal-title":"Bioinformatics."},{"key":"1857_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00019052-200106000-00003","volume":"14","author":"C Bjartmar","year":"2001","unstructured":"Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr.Opin.Neurol. 14:271","journal-title":"Curr.Opin.Neurol."},{"key":"1857_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0022-510X(99)00178-1","volume":"170","author":"E Silber","year":"1999","unstructured":"Silber E, Sharief MK (1999) Axonal degeneration in the pathogenesis of multiple sclerosis. J.Neurol.Sci. 170:11","journal-title":"J.Neurol.Sci."},{"key":"1857_CR27","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1167\/iovs.12-11026","volume":"54","author":"MR Banitt","year":"2013","unstructured":"Banitt MR, Ventura LM, Feuer WJ, Savatovsky E, Luna G, Shif O, Bosse B, Porciatti V (2013) Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest Ophthalmol.Vis.Sci. 54:2346","journal-title":"Invest Ophthalmol.Vis.Sci."},{"key":"1857_CR28","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1523\/JNEUROSCI.4443-07.2008","volume":"28","author":"BP Buckingham","year":"2008","unstructured":"Buckingham BP, Inman DM, Lambert W, Oglesby E, Calkins DJ, Steele MR, Vetter ML, Marsh-Armstrong N et al (2008) Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J.Neurosci. 28:2735","journal-title":"J.Neurosci."},{"key":"1857_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ana.22109","volume":"69","author":"GR Campbell","year":"2011","unstructured":"Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, Lassmann H, Turnbull DM et al (2011) Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann.Neurol. 69:481","journal-title":"Ann.Neurol."},{"key":"1857_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0022-510X(00)00343-9","volume":"177","author":"F Lu","year":"2000","unstructured":"Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C, Kalman B (2000) Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J.Neurol.Sci. 177:95","journal-title":"J.Neurol.Sci."},{"key":"1857_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/path.2582","volume":"219","author":"ME Witte","year":"2009","unstructured":"Witte ME, Bo L, Rodenburg RJ, Belien JA, Musters R, Hazes T, Wintjes LT, Smeitink JA et al (2009) Enhanced number and activity of mitochondria in multiple sclerosis lesions. J.Pathol. 219:193","journal-title":"J.Pathol."},{"key":"1857_CR32","doi-asserted-by":"crossref","unstructured":"Kumleh HH, Riazi GH, Houshmand M, Sanati MH, Gharagozli K, Shafa M (2006) Complex I deficiency in Persian multiple sclerosis patients. J.Neurol.Sci","DOI":"10.1016\/j.jns.2005.11.030"},{"key":"1857_CR33","first-page":"1516","volume":"13","author":"TM Bosley","year":"2007","unstructured":"Bosley TM, Constantinescu CS, Tench CR, bu-Amero KK (2007) Mitochondrial changes in leukocytes of patients with optic neuritis. Mol.Vis. 13:1516","journal-title":"Mol.Vis."},{"key":"1857_CR34","doi-asserted-by":"publisher","first-page":"9167","DOI":"10.1073\/pnas.95.16.9167","volume":"95","author":"BB Seo","year":"1998","unstructured":"Seo BB, Kitajima-Ihara T, Chan EK, Scheffler IE, Matsuno-Yagi A, Yagi T (1998) Molecular remedy of complex I defects: rotenone-insensitive internal NADH-quinone oxidoreductase of Saccharomyces cerevisiae mitochondria restores the NADH oxidase activity of complex I-deficient mammalian cells. Proc.Natl.Acad.Sci.U.S.A 95:9167","journal-title":"Proc.Natl.Acad.Sci.U.S.A"},{"key":"1857_CR35","doi-asserted-by":"publisher","first-page":"37774","DOI":"10.1074\/jbc.M007033200","volume":"275","author":"BB Seo","year":"2000","unstructured":"Seo BB, Wang J, Flotte TR, Yagi T, Matsuno-Yagi A (2000) Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells. J.Biol.Chem. 275:37774","journal-title":"J.Biol.Chem."},{"key":"1857_CR36","doi-asserted-by":"crossref","unstructured":"Bai Y, Hajek P, Chomyn A, Chan E, Seo BB, Matsuno-Yagi A, Yagi T, Attardi G (2001) Lack of complex I activity in human cells carrying a mutation in MtDNA- encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH- Quinone Oxidoreductase (NDI1) gene. J.Biol.Chem","DOI":"10.1074\/jbc.M106363200"},{"key":"1857_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1474-9726.2010.00546.x","volume":"9","author":"S Bahadorani","year":"2010","unstructured":"Bahadorani S, Cho J, Lo T, Contreras H, Lawal HO, Krantz DE, Bradley TJ, Walker DW (2010) Neuronal expression of a single-subunit yeast NADH-ubiquinone oxidoreductase (Ndi1) extends Drosophila lifespan. Aging Cell 9:191","journal-title":"Aging Cell"},{"key":"1857_CR38","doi-asserted-by":"crossref","unstructured":"DeCorby A, Gaskova D, Sayles LC, Lemire BD (2007, 1767) Expression of Ndi1p, an alternative NADH:ubiquinone oxidoreductase, increases mitochondrial membrane potential in a C. elegans model of mitochondrial disease. Biochim.Biophys.Acta:1157","DOI":"10.1016\/j.bbabio.2007.07.003"},{"key":"1857_CR39","doi-asserted-by":"publisher","first-page":"e11472","DOI":"10.1371\/journal.pone.0011472","volume":"5","author":"M Marella","year":"2010","unstructured":"Marella M, Seo BB, Thomas BB, Matsuno-Yagi A, Yagi T (2010) Successful amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in a rat animal model. PLoS.One 5:e11472","journal-title":"PLoS.One"},{"key":"1857_CR40","doi-asserted-by":"publisher","first-page":"e25910","DOI":"10.1371\/journal.pone.0025910","volume":"6","author":"M Marella","year":"2011","unstructured":"Marella M, Seo BB, Flotte TR, Matsuno-Yagi A, Yagi T (2011) No immune responses by the expression of the yeast Ndi1 protein in rats. PLoS.One 6:e25910","journal-title":"PLoS.One"},{"key":"1857_CR41","doi-asserted-by":"crossref","unstructured":"Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE et al (2008) Effect of gene therapy on visual function in Leber's congenital Amaurosis. N.Engl.J.Med","DOI":"10.1056\/NEJMoa0802268"},{"key":"1857_CR42","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","volume":"374","author":"AM Maguire","year":"2009","unstructured":"Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL et al (2009) Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374:1597","journal-title":"Lancet"},{"key":"1857_CR43","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA et al (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N.Engl.J.Med 358:2240","journal-title":"N.Engl.J.Med"},{"key":"1857_CR44","first-page":"979","volume":"19","author":"WW Hauswirth","year":"2008","unstructured":"Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL et al (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. HumGene Ther 19:979","journal-title":"HumGene Ther"},{"key":"1857_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K et al (2006) Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat.Med. 12:342","journal-title":"Nat.Med."},{"key":"1857_CR46","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","volume":"101","author":"CS Manno","year":"2003","unstructured":"Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV et al (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963","journal-title":"Blood"},{"key":"1857_CR47","doi-asserted-by":"publisher","first-page":"124S","DOI":"10.1378\/chest.120.3_suppl.124S","volume":"120","author":"TR Flotte","year":"2001","unstructured":"Flotte TR, Laube BL (2001) Gene therapy in cystic fibrosis. Chest 120:124S","journal-title":"Chest"},{"key":"1857_CR48","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097","journal-title":"Lancet"},{"key":"1857_CR49","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/01.icu.0000188705.67815.0e","volume":"16","author":"RC Sergott","year":"2005","unstructured":"Sergott RC (2005) Optical coherence tomography: measuring in-vivo axonal survival and neuroprotection in multiple sclerosis and optic neuritis. Curr.Opin.Ophthalmol. 16:346","journal-title":"Curr.Opin.Ophthalmol."},{"key":"1857_CR50","doi-asserted-by":"publisher","first-page":"7739","DOI":"10.1167\/iovs.14-15388","volume":"55","author":"R Koilkonda","year":"2014","unstructured":"Koilkonda R, Yu H, Talla V, Porciatti V, Feuer WJ, Hauswirth WW, Chiodo V, Erger KE et al (2014) LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: Biodistribution and toxicology profile. Invest Ophthalmol.Vis.Sci. 55:7739","journal-title":"Invest Ophthalmol.Vis.Sci."},{"key":"1857_CR51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/14712598.2012.681463","volume":"12","author":"RD Dayton","year":"2012","unstructured":"Dayton RD, Wang DB, Klein RL (2012) The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert.Opin.Biol.Ther. 12:757","journal-title":"Expert.Opin.Biol.Ther."},{"key":"1857_CR52","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"S Duque","year":"2009","unstructured":"Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P et al (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol.Ther. 17:1187","journal-title":"Mol.Ther."}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-01857-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-019-01857-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-01857-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:34:50Z","timestamp":1695576890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-019-01857-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1857"],"URL":"https:\/\/doi.org\/10.1007\/s12035-019-01857-6","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The protocol for the study was approved by the University of Miami Institutional Animal Care and Use Committee, and all the procedures were conducted in accordance with the United States Public Health Service\u2019s Policy on Humane Care and Use of Laboratory Animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}